Skip to main content

Table 2 Associations of aldehyde dehydrogenase 1 expression with clinicopathological factors according to time of recurrence

From: Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

  Early recurrence Late recurrence No recurrence
  ALDH1+ ALDH1 p Value ALDH1+ ALDH1 p Value ALDH1+ ALDH1 p Value
Age, years          
  ≤ 50 15 (44.12) 67 (44.67) 0.981 10 (55.56) 39 (33.62) 0.077 12 (44.44) 108 (36.73) 0.432
  > 50 19 (55.88) 83 (55.33)   8 (44.44) 77 (66.38)   15 (55.56) 186 (63.27)
Tumor size, mm          
  ≤ 20 9 (26.47) 40 (26.67) 0.981 4 (22.22) 40 (34.48) 0.288 15 (55.56) 172 (58.50) 0.766
  > 20 25 (73.53) 110 (73.33)   14 (77.78) 76 (65.52)   12 (44.44) 122 (41.50)
Lymph node metastasis          
 Negative 12 (35.29) 81 (54.00) 0.047 7 (38.89) 72 (62.07) 0.065 23 (85.19) 244 (82.99) 0.767
 Positive 22 (64.71) 69 (46.00)   11 (61.11) 44 (37.93)   4 (14.81) 50 (17.01)  
Estrogen receptor staining          
  < 10 % 3 (8.82) 13 (8.67) 0.559 2 (11.11) 8 (6.90) 0.335 3 (11.11) 24 (8.16) 0.831
 10–50 % 8 (23.53) 49 (32.67)   8 (44.44) 35 (30.17)   6 (22.22) 76 (25.85)  
  ≥ 50 % 23 (67.65) 88 (58.67)   8 (44.44) 73 (62.93)   18 (66.67) 194 (65.99)
Progesterone receptor staining          
  ≤ 20 % 14 (41.18) 71 (47.33) 0.514 7 (38.89) 52 (44.83) 0.635 13 (48.15) 120 (40.82) 0.461
  > 20 % 20 (58.82) 79 (52.67)   11 (61.11) 64 (55.17)   14 (51.85) 174 (59.18)
Histological grade          
 1 or 2 25 (73.53) 106 (70.67) 0.736 11 (61.11) 95 (81.90) 0.058 25 (92.59) 253 (86.05) 0.305
 3 9 (26.47) 44 (29.33)   7 (38.89) 21 (18.10)   2 (7.41) 41 (13.95)  
Ki-67 staining          
  ≤ 20 % 17 (50.00) 119 (79.33) <0.001 14 (77.78) 100 (86.21) 0.373 20 (74.07) 245 (83.33) 0.247
  > 20 % 17 (50.00) 31 (20.67)   4 (22.22) 16 (13.79)   7 (25.93) 49 (16.67)  
  1. ALDH1 aldehyde dehydrogenase 1